Search research articles
Contact Us
Filters
Showing results (61-70 of 79) with videos related to
Page
of 8
Sort By:
Haematologica
|
July 20, 2023
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia
Ibrahim Aldoss, Parastou Tizro, Davsheen Bedi, et al.
Leukemia & Lymphoma
|
October 6, 2023
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia
Daria Gaut, Caspian Oliai, Jonathan Boiarsky, et al.
Blood Cancer Journal
|
July 3, 2021
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes
Ibrahim Aldoss, Raju Pillai, Dongyun Yang, et al.
Cell Reports. Medicine
|
June 16, 2026
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care
Aritro Nath, Jyoti Malhotra, Isa Mambetsariev, et al.
Blood Advances
|
January 10, 2019
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen
Haris Ali, Ibrahim Aldoss, Dongyun Yang, et al.
Leukemia & Lymphoma
|
September 12, 2022
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
Brian J Ball, Shukaib Arslan, Paul Koller, et al.
The American Journal of Surgical Pathology
|
August 30, 2022
NUTM1 -rearranged Carcinoma of the Thyroid : A Distinct Subset of NUT Carcinoma Characterized by Frequent NSD3 - NUTM1 Fusions
Justine A Barletta, Steven D Gilday, Michelle Afkhami, et al.
Leukemia & Lymphoma
|
August 3, 2023
<i>WT1</i>-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens
Ahmed Aribi, Amandeep Salhotra, Michelle Afkhami, et al.
Bone Marrow Transplantation
|
December 18, 2024
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease
Amanda Blackmon, Michelle Afkhami, Dongyun Yang, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 4, 2019
Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations
Amandeep Salhotra, Michelle Afkhami, Dongyun Yang, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 79) with videos related to
Sort By:
Page
of 8
Haematologica
|
July 20, 2023
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia
Ibrahim Aldoss, Parastou Tizro, Davsheen Bedi, et al.
Leukemia & Lymphoma
|
October 6, 2023
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia
Daria Gaut, Caspian Oliai, Jonathan Boiarsky, et al.
Blood Cancer Journal
|
July 3, 2021
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes
Ibrahim Aldoss, Raju Pillai, Dongyun Yang, et al.
Cell Reports. Medicine
|
June 16, 2026
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care
Aritro Nath, Jyoti Malhotra, Isa Mambetsariev, et al.
Blood Advances
|
January 10, 2019
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen
Haris Ali, Ibrahim Aldoss, Dongyun Yang, et al.
Leukemia & Lymphoma
|
September 12, 2022
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
Brian J Ball, Shukaib Arslan, Paul Koller, et al.
The American Journal of Surgical Pathology
|
August 30, 2022
NUTM1 -rearranged Carcinoma of the Thyroid : A Distinct Subset of NUT Carcinoma Characterized by Frequent NSD3 - NUTM1 Fusions
Justine A Barletta, Steven D Gilday, Michelle Afkhami, et al.
Leukemia & Lymphoma
|
August 3, 2023
<i>WT1</i>-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens
Ahmed Aribi, Amandeep Salhotra, Michelle Afkhami, et al.
Bone Marrow Transplantation
|
December 18, 2024
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease
Amanda Blackmon, Michelle Afkhami, Dongyun Yang, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 4, 2019
Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations
Amandeep Salhotra, Michelle Afkhami, Dongyun Yang, et al.
Page
of 8